Daratumumab/rHuPH20

DRUG3 trials

Sponsors

Genentech, Inc., SWOG Cancer Research Network, Masonic Cancer Center, University of Minnesota

Conditions

Acute Myeloid LeukemiaB-Cell LymphomaMonocytic LeukemiaMultiple MyelomaMyeloid LeukemiaNon-Hodgkin Lymphoma

Phase 1

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), and Preliminary Activity of Tiragolumab in Participants With Relapsed or Refractory Multiple Myeloma or With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

TerminatedNCT04045028

Genentech, Inc.B-Cell Lymphoma, Multiple Myeloma, Non-Hodgkin Lymphoma

Start: 2019-07-22End: 2023-03-28Updated: 2023-04-07

FT538 in Combination With Daratumumab in AML Acute Myeloid Leukemia

CompletedNCT04714372

Masonic Cancer Center, University of MinnesotaAcute Myeloid Leukemia, Monocytic Leukemia, Myeloid Leukemia

Start: 2021-11-03End: 2024-10-15Updated: 2024-10-24

Phase 3

S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct Therapy Duration

Active, not recruitingNCT04071457

SWOG Cancer Research NetworkMultiple Myeloma

Start: 2019-08-13End: 2040-07-01Target: 1100Updated: 2026-09-17

Related Papers

Daratumumab Versus Lenalidomide As Maintenance Therapy in Newly Diagnosed Multiple Myeloma - Interim Efficacy Results of a Randomized Clinical Trial

Blood2024-11-05

Trial in Progress: Iberdomide and Daratumumab As Maintenance Therapy after an Autologous Stem Cell Transplant for Multiple Myeloma (the IBEX Trial)

Blood2024-11-05

Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study

Blood2024-09-2736 citations

Phase I Study of FT538 + Daratumumab for Treatment of r/r AML

Blood2023-11-025 citations

365 Oxygen levels found in bone marrow (5%) provide an optimal niche for the differentiation of induced-pluripotent stem cell-derived NK cells for the treatment of AML

Regular and Young Investigator Award Abstracts2023-10-31

Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature.

2023-08-075 citations

MRD dynamics during maintenance for improved prognostication of 1280 patients with myeloma in the TOURMALINE-MM3 and -MM4 trials

Blood2022-09-2149 citations

Biomarker Analysis of a Phase Ia/Ib Open-Label, Multicentre Study of Tiragolumab or Tiragolumab + Rituximab in Patients with Relapsed or Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (NHL)

Blood2021-11-054 citations